skip to the content

Clinical Trials

MIF - Spinal Cord Injury Study

GCRC 0268:Pilot Study: The Role of MIF in Spinal Cord Injury

Protocol ID

09-026

Protocol Description

The purpose of this study is to evaluate substances that may be present in the blood after a spinal cord injury (SCI). Specifically, the study will evaluate the presence and levels of a protein, macrophage migration inhibitory factor (MIF), in the blood of patients who have had a SCI. Blood samples from patients who have had a SCI and uninjured individuals will be studied to measure MIF levels. MIF is released by cells and has a specific effect on the way cells behave, communicate and work together. In several other medical conditions, MIF is known to increase inflammation in the body. By comparing blood samples from spinal cord injury patients and normal uninjured individuals, the investigators will try to find out if MIF levels are increased in people with SCI. Investigators will also use these samples to see if the biological activities of MIF can be reduced in a test tube by adding other substances to the blood samples.  It is hoped that this study of MIF will help improve the treatment of SCI in the future. Other factors in the blood, including inflammatory proteins and hormones (substances that can affect MIF levels), will be tested.

Eligibility Criteria

Patients who have had a spinal cord injury

Primary Investigator(s)

  • Ona Bloom, PhD

Contact Information

Ona Bloom, PhD
(516) 562-3839
obloom@nshs.edu

Last Update

April 12, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Neurosciences:
top
top